Hemonc Today | Proton therapy (PT) is a potentially important radiation modality for primary brain tumors due to its unique dose distributions. Unlike photon radiation, PT dose is characterized by a well-defined maximal range where the majority of the dose is deposited, followed by a rapid dose falloff to zero distally within a mere few millimeters.This unique dosimetric profile is highly…

Results of early clinical trials suggest that chimeric antigen receptor T cells can be adapted successfully to target brain tumors, according to a presenter at AACR Virtual Special Conference: Brain Cancer.A phase 1 analysis of one next-generation CAR T-cell therapy showed it may target and kill tumor cells while eliciting an immune system response to help aid in that effort, according to

Patients with isocitrate dehydrogenase wild-type glioblastoma who used levetiracetam for the duration of chemoradiation may have a higher overall survival rate, according to an observational, retrospective cohort study in Neurology.“In patients with [isocitrate dehydrogenase (IDH)] wild-type glioblastoma, epileptic seizures are common during the course of the tumor, with incidence ranging

Researchers reported common causes of death and end-of-life care experiences among patients with intracranial high-grade gliomas in a retrospective observational study published in Neurology. “Uncertainty surrounding end-of-life expectations, including whether death involves physical pain or suffering, may exacerbate anxiety among patients and caregivers, who often ask about end-of-life

A personalized cancer vaccine conferred a PFS benefit to a subset of patients with newly diagnosed glioblastoma, according to phase 2 study results presented at Society for the Immunotherapy of Cancer Annual Meeting. Patients with primary glioblastoma who had methylation of the O-6-methylguanine-DNA methyltransferase (MGMT) gene promoters, as well as those who had mutation of the gene for